Last reviewed · How we verify
varicella-1
varicella-1 is a Biologic drug developed by Changchun Keygen Biological Products Co., Ltd.. It is currently FDA-approved.
Varicella-1 is a live attenuated varicella vaccine used to study its immunogenicity and safety in clinical trials. It has been studied in conditions such as varicella and hepatitis A, and is administered in combination with other varicella vaccines, including varicella-3 and varicella-5.
At a glance
| Generic name | varicella-1 |
|---|---|
| Sponsor | Changchun Keygen Biological Products Co., Ltd. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine (PHASE4)
- Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- varicella-1 CI brief — competitive landscape report
- varicella-1 updates RSS · CI watch RSS
- Changchun Keygen Biological Products Co., Ltd. portfolio CI
Frequently asked questions about varicella-1
What is varicella-1?
Who makes varicella-1?
What development phase is varicella-1 in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing